These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33969485)

  • 1. Systematic review and meta-analysis on the impact of the levonorgestrel-releasing intrauterine system in reducing risk of ovarian cancer.
    D'Alessandro G; Frigerio M; Barra F; Costantini S; Gustavino C; Ferrero S
    Int J Gynaecol Obstet; 2022 Mar; 156(3):418-424. PubMed ID: 33969485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis.
    Conz L; Mota BS; Bahamondes L; Teixeira Dória M; Françoise Mauricette Derchain S; Rieira R; Sarian LO
    Acta Obstet Gynecol Scand; 2020 Aug; 99(8):970-982. PubMed ID: 31990981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby A; Hussain M; Rishworth JR; Rees MC
    Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
    Jareid M; Thalabard JC; Aarflot M; Bøvelstad HM; Lund E; Braaten T
    Gynecol Oncol; 2018 Apr; 149(1):127-132. PubMed ID: 29482839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Dominick S; Hickey M; Chin J; Su HI
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby AE; Cooke I; Rees M
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Romero SA; Young K; Hickey M; Su HI
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.
    Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Pukkala E
    Acta Oncol; 2016 Nov; 55(11):1281-1284. PubMed ID: 27148621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery.
    Abou-Setta AM; Al-Inany HG; Farquhar CM
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005072. PubMed ID: 17054236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
    Krashin J; Tang JH; Mody S; Lopez LM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD009805. PubMed ID: 26280888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of levonorgestrel releasing intrauterine system as a postoperative maintenance therapy of endometriosis: A meta-analysis.
    Song SY; Park M; Lee GW; Lee KH; Chang HK; Kwak SM; Yoo HJ
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():85-92. PubMed ID: 30336309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of different doses levonorgestrel-releasing intrauterine system (LNG-IUS): real-world data from a multicenter Italian study.
    Bastianelli C; Farris M; Rosato E; Varliero F; Del Savio MC; Facchinetti F; Grandi G
    Eur J Contracept Reprod Health Care; 2022 Feb; 27(1):16-22. PubMed ID: 34528867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence.
    Cho S; Jung JA; Lee Y; Kim HY; Seo SK; Choi YS; Lee JS; Lee BS
    Acta Obstet Gynecol Scand; 2014 Jan; 93(1):38-44. PubMed ID: 24605384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
    Wan YL; Holland C
    Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects.
    da Silva AV; de Melo AS; Barboza RP; de Paula Martins W; Ferriani RA; Vieira CS
    Reprod Sci; 2016 Jul; 23(7):877-84. PubMed ID: 26733500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies.
    Apter D; Gemzell-Danielsson K; Hauck B; Rosen K; Zurth C
    Fertil Steril; 2014 Jun; 101(6):1656-62.e1-4. PubMed ID: 24726226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy.
    Graner S; Mc Taggart J; Nordström F; Melander E; Widenberg J; Kopp Kallner H
    Acta Obstet Gynecol Scand; 2019 Jul; 98(7):937-943. PubMed ID: 30737766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.